Yellow Fever Vaccine Information
Sanofi Pasteur expects YF-VAX® (Yellow Fever Vaccine) supply to return in the U.S. by the end of 2018 as the company transitions production to a new state-of-the-art facility. In the interim, Sanofi Pasteur has worked with the FDA to make another yellow fever vaccine available in the US through an Expanded Access Investigational New Drug Application (IND). Manufactured by Sanofi Pasteur in France, this vaccine, STAMARIL® (Yellow Fever Vaccine [Live]), is registered and distributed in over 70 countries. However, it is considered investigational in the US, as it is not a US-licensed product.
The Expanded Access Program has requirements similar to a clinical trial; thus Sanofi Pasteur can support only a limited number of sites. Working closely with the CDC, more than 250 geographically distributed sites throughout the US were identified for inclusion in the program so patients can have continued access to yellow fever vaccine.
Health care providers and patients may find locations that can administer STAMARIL vaccine by visiting the CDC web page at http://wwwnc.cdc.gov/travel/yellow-fever-vaccination-clinics/search. New clinics will be continually added as they complete the certification process.
Providers and patients may also visit http://wwwnc.cdc.gov/travel for information about which countries require yellow fever vaccination for entry and for which countries the CDC recommends yellow fever vaccination.